Skip to main content
SpringerLink
Log in

Cardiovascular Pharmacology of Hormone Replacement Therapy

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The incidence of cardiovascular disease in women is negligible before natural or surgically-induced menopause, and increases after menopause. Epidemiological data suggest that estrogen replacement therapy reduces the occurrence of coronary artery, and possibly cerebrovascular, disease by 25 to 50% in treated women compared with non-users. These findings are supported by the evidence that estrogens have a beneficial effect on cholesterol metabolism and deposition, contributing to the inhibition of atherosclerotic plaque formation in arterial walls. Early reports suggested that up to 60% of the protective effect of estrogens on coronary artery disease was attributable to favourable changes in plasma lipids. Reanalysis of the data indicated that the lipid changes probably account for approximately 25% of the cardioprotective effect of estrogens and that other effects are, therefore, likely to be important. The influence of estrogens on carbohydrate metabolism, atheroma formation and cardiovascular haemodynamics may also play an integral role in the overall beneficial effect of the hormones. Animal and human studies have shown that the administration of estrogens leads to a restoration of endothelial function, an increase in cardiac output, an increase in arterial flow velocity, a decrease in vascular resistance, and a decrease in systolic and diastolic blood pressure. Recent studies on hormone replacement regimens have shown that estrogens may favourably affect fibrinolysis and reduce plasma fibrinogen to premenopausal levels.

Despite these effects of estrogens the recent Heart and Estrogen/Progestin Replacement Study (HERS) failed to show a cardioprotective effect of hormone replacement therapy (HRT) in elderly women with coronary artery disease. However, the HERS study has several limitations and stands alone against the large body of evidence that suggest that HRT may reduce cardiovascular mortality and morbidity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wuest JH, Dry TJ, Edwards JE. Circulation 1953; 7: 801–8

    PubMed  Google Scholar 

  2. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280(7): 605–13

    PubMed  CAS  Google Scholar 

  3. Bush TI, Barret-Connor E, Cowan LD. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102–9

    PubMed  CAS  Google Scholar 

  4. Hunt K, Vessey M, McPherson K, et al. Long-term surveillance mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 1987; 94: 620–35

    PubMed  CAS  Google Scholar 

  5. Grodstein F, Samfer MJ, Colditz GA, et al. Postmenopausal hormone replacement therapy and mortality. N Engl J Med 1997; 336: 1769–75

    PubMed  CAS  Google Scholar 

  6. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47–63

    PubMed  CAS  Google Scholar 

  7. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Ateriosclerosis 1993; 98: 83–90

    CAS  Google Scholar 

  8. Wagner JD, St Clair RW, Schwenke DC, et al. Regional differences in arterial low density lipoprotein metabolism in surgically postmenopausal cynomolgus monkeys. Arterioscler Thromb 1992; 12: 717–26

    PubMed  CAS  Google Scholar 

  9. Libby P. Disorders of the cardiovascular system. Section 4: vascular disease, atherosclerosis. In: Fauci A, Braunwald E, Isselbacher KJ, et al., editors. Harrisons principles of internal medicine part eight. New York: Mcgraw-Hill, 1998: 234–56

    Google Scholar 

  10. Ley CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body fat distribution. Am J Clin Nutr 1992; 55: 950–4

    PubMed  CAS  Google Scholar 

  11. Stout R. Insulin and atheroma: 20-year perspective. Diabetes Care 1990; 13: 631–54

    PubMed  CAS  Google Scholar 

  12. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607

    PubMed  CAS  Google Scholar 

  13. Olofson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10: 77–82

    Google Scholar 

  14. Walton C, Godsland I, Proudler A, et al. The effects of menopause on carbohydrate metabolism in healthy women [abstract]. J Endocrinol 1991; 129 Suppl.: 97

    Google Scholar 

  15. Godsland IF, Wynn V, Crook D, et al. Sex, plasma lipoproteins and atherosclerosis: prevailing assumptions and outstanding questions. Am Heart J 1987; 114: 1467–503

    PubMed  CAS  Google Scholar 

  16. Scarabin PY, Bonithon-Kopp C, Bara L, et al. Factor VII activation and menopausal status. Thromb Res 1990; 57: 227–34

    PubMed  CAS  Google Scholar 

  17. Folsom AR, Wu KK, Davis CE, et al. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Arteriosclerosis 1991; 91: 191–205

    CAS  Google Scholar 

  18. Heinrich J, Sandkamp M, Kokott R, et al. Relationship of lipoprotein (a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem 1991; 37: 1950–4

    PubMed  CAS  Google Scholar 

  19. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990; 81: 1680–7

    PubMed  CAS  Google Scholar 

  20. Adams MR, Register TC, Wagner JD, et al. Effects of estrogens and progestins on the pathogenes is of atherosclerosis in nohuman primate. In: Forte TM, editor. Hormonal, metabolic and cellular influences on cardiovascular disease in women. New York: Futura Publishing Company, Inc., 1997: 39–53

    Google Scholar 

  21. Geary RL, Adams RL, Benjamin ME, et al. Conjugated equine estrogens inhibit progression of atherosclerosis but have no effect on intimai hyperplasia or arterial remodeling induced balloon catheter injury in monkeys. J Am Coll Cardiol 1998; 31: 1158–64

    PubMed  CAS  Google Scholar 

  22. Gruchow HW, Anderson AJ, Barboriak JJ, et al. Post-menopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988; 115: 954–63

    PubMed  CAS  Google Scholar 

  23. O’Keefe JH, Kim SC, Hall RR, et al. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997; 29(1): 1–5

    PubMed  Google Scholar 

  24. Maseri A, LAbbate A, Chierchia S, et al. Significance of spasm in the pathogenesis of ischemic heart disease. Am J Cardiol 1979; 44: 788–92

    PubMed  CAS  Google Scholar 

  25. Magness RR, Rosenfeld CR. Local and systemic estradiol 17β: effects on uterine and systemic vasodilation. Am J Physiol 1989; 256: E536–42

    PubMed  CAS  Google Scholar 

  26. Killam AP, Rosenfeld CR, Battaglia FC, et al. Effect of estrogens on the uterine blood flow of oophorectomized ewes. Am J Obstet Gynecol 1973; 115: 1045–52

    PubMed  CAS  Google Scholar 

  27. Volterrani M, Rosano GMC, Coats A, et al. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am J Med 1995; 99: 119–22

    PubMed  CAS  Google Scholar 

  28. Ganger KF, Vyas S, Whitehead M, et al. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991; 338: 839–42

    Google Scholar 

  29. Penotti M, Nencioni T, Gabrielli L, et al. Blood flow variations in internal carotid and middle cerebral arteries induced by postmenopausal hormone replacement therapy. Am J Obstet Gynecol 1993; 169: 1226–32

    PubMed  CAS  Google Scholar 

  30. Reis SE, Gloth ST, Blumenthal RS. Ethinyl estradiol attenuates abnormal coronary vasomotor response to acetylcholine in postmenopausal women. Circulation 1994; 89; 52–60

    PubMed  CAS  Google Scholar 

  31. Gilligan DM, Quyuni AA, Cannon III RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994; 89: 2545–51

    PubMed  CAS  Google Scholar 

  32. Collins P, Rosano GMC, Sarrel PM, et al. Oestradiol 17β attenuates acetylcholine induced coronary arterial constriction in women but not in men with coronary artery disease. Circulation 1995; 92: 24–30

    PubMed  CAS  Google Scholar 

  33. Gordon T, Kannel WB, Hjortland MC, et al. Menopause and coronary heart disease: the Framingham Study. Ann Intern Med 1978; 89: 157–71

    PubMed  CAS  Google Scholar 

  34. Paganini-Hill A, Ross R, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 1989; 297: 519–22

    Google Scholar 

  35. Rosano GMC, Sarrel PM, Poole-Wilson PA, et al. Beneficial effect of oestrogen on exercise-induced myocardial ischemia in women with coronary artery disease. Lancet 1993; 342: 1133–6

    Google Scholar 

  36. Samsioe G. Effects of estrogen in various lipid constituents. Consultant 1990; 30: 58–62

    Google Scholar 

  37. Tikkanen M, Nikkala EA, Kuusi T, et al. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab 1982; 54: 1113–7

    PubMed  CAS  Google Scholar 

  38. Srivastava RAK, Baumann D, Schonfeld G. In vivo regulation of LDL receptors by estrogen differs at the post-transcriptional level in rat and mouse. Eur J Biochem 1993; 216: 527–38

    PubMed  CAS  Google Scholar 

  39. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196–204

    PubMed  CAS  Google Scholar 

  40. Soma M, Fumagalli R, Paoletti R, et al. Plasma Lp(a) concentration after estrogen and progestogen in postmenopausal women. Lancet 1991; 337: 612–19

    PubMed  CAS  Google Scholar 

  41. Sullivan JM, Vander Zwaag R, Lemp GF, et al. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988; 108: 358–63

    PubMed  CAS  Google Scholar 

  42. Bush TL, Miller VT. Effects of pharmacologic agents used during menopause: impact on lipids and lipoproteins. In: Mishell Jr D, editor. Menopause: physiology and pharmacology. Chicago (IL): Year Book Medical, 1986: 187–208

    Google Scholar 

  43. The Postmenopausal Estrogen/Progestin Intervention Trial Writing Group. Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199–208

    Google Scholar 

  44. Cagnacci A, Soldani R, Carriero PL, et al. Effects of low doses of trans dermal 17β-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 1992; 74: 1396–400

    PubMed  CAS  Google Scholar 

  45. Pick R, Stamler J, Rodbard S, et al. The inhibition of coronary atherosclerosis by estrogen in cholesterol-fed chicks. Circulation 1952; 6: 276–80

    PubMed  CAS  Google Scholar 

  46. Stamler J, Pick R, Katz LN. Prevention of coronary atherosclerosis by estrogen-androgen administration in the cholesterol-fed chick. Circ Res 1953; 1: 94–101

    PubMed  CAS  Google Scholar 

  47. Sack MN, Rader DJ, Cannon III RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994; 343: 269–70

    PubMed  CAS  Google Scholar 

  48. Simon BC, Cunningham LD, Cohen RA. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest 1990; 86: 75–9

    PubMed  CAS  Google Scholar 

  49. Notelowitz M, Johnston M, Smith S, et al. Metabolic and hormonal effects of 25 mg and 50 mg 17B estradiol implants in surgically menopausal women. Obstet Gynecol 1987; 70: 749–54

    Google Scholar 

  50. Godsland IF, Gangar KF, Walton C, et al. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993; 42: 846–53

    PubMed  CAS  Google Scholar 

  51. Sporrong T, Mattsson LA, Samsioe G, et al. Hemostatic changes during continuous estradiol-progestogen treatment of postmenopausal women. Br J Obstet Gynaecol 1990; 97: 939–44

    PubMed  CAS  Google Scholar 

  52. Gebara OCE, Mittlemann MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995; 91: 1952–8

    PubMed  CAS  Google Scholar 

  53. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683–90

    PubMed  CAS  Google Scholar 

  54. Devor M, Barrett-Connor E, Renvall M, et al. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275–82

    PubMed  CAS  Google Scholar 

  55. Horowitz KB, Horowitz LD. Canine vascular tissues are targets for androgens, estrogens, progestins and glucocorticoids. J Clin Invest 1982; 69: 750–8

    Google Scholar 

  56. Lin AL, McGill HC, Shain SA. Hormone receptors of the baboon cardiovascular system. Circ Res 1982; 50: 610–6

    PubMed  CAS  Google Scholar 

  57. McGill Jr HC. Sex steroid hormone receptors in the cardiovascular system. Postgrad Med 1989 Apr; 64–8; 89–90

    Google Scholar 

  58. Kahn D, Zeng Q, Kajani M, et al. The effect of different types of hepatic injury on the estrogen and androgen receptor activity of liver. J Invest Surg 1989; 2: 125–33

    PubMed  CAS  Google Scholar 

  59. Williams SP, Shackelford DP, Larns SG, et al. Endothelium-dependent relaxation in estrogen-treated spontaneously hypertensive rats. Eur J Pharmacol 1988; 145: 205–7

    PubMed  CAS  Google Scholar 

  60. Gisclard V, Miller VM, Vanhoutte PM. Effect of 17β-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther 1988; 244: 19–22

    PubMed  CAS  Google Scholar 

  61. Gilligan DM, Badar DM, Panza JA, et al. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994; 90: 786–91

    PubMed  CAS  Google Scholar 

  62. Weiner CP, Lizasoain I, Baylis SA, et al. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A 1994; 91: 5212–6

    PubMed  CAS  Google Scholar 

  63. Dubey RK, Overbeck HW. Culture of rat mesenteric arteriolar smooth muscle cells: effects of platelet-derived growth factor, angiotensin, and nitric oxide on growth. Cell Tissue Res 1994; 275: 133–41

    PubMed  CAS  Google Scholar 

  64. Hayashi T, Fukuto JM, Ignarro LJ, et al. Basal release of nitric oxide from aortic rings is greater in female rabbits than in male rabbits: implications for atherosclerosis. Proc Natl Acad Sci U S A 1992; 8: 11259–63

    Google Scholar 

  65. Schray-Utz B, Zeiher AM, Busse R. Expression of constitutive NO synthase in cultured endothelial cells is enhanced by 17fiestradiol [abstract]. Circulation 1993; 88: 1–8

    Google Scholar 

  66. Sayegh HS, Ohara Y, Navas JP, et al. Endothelial nitric oxide synthase regulation by estrogens [abstract]. Circulation 1993; 88(4): 1–80

    Google Scholar 

  67. Caulin-Glaser TL, Sessa W, Sarrel P, et al. The effect of 17fl-estradiol on human endothelial cell nitric oxide production [abstract]. Circulation 1994; 90: 1–30

    Google Scholar 

  68. Miller VM, Gisclard V, Vanhoutte PM. Modulation of endothelium-dependent and vascular smooth muscle responses by estrogens. Phlebologie 1988; 224: 19–22

    Google Scholar 

  69. Koudy Williams J, Adams MR, Klopfenstein MD. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990: 81: 1680–7

    Google Scholar 

  70. Collins A, Eneroth P, Landgren BM, et al. Psyconeuroendocrine stress responses and mood as related to the menstrual cycle. Psychosom Med 1985; 47: 512–27

    PubMed  CAS  Google Scholar 

  71. Rosano GMC, Leonardo F, Ponikowski P, et al. Estrogen replacement therapy normalizes the autonomie control of the cardiovascular system in menopausal women [abstract]. J Am Coll Cardiol 1996; 27: 2 Suppl. A

    Google Scholar 

  72. Hamlet MA, Rorie DK, Tyce GM. Effects of estradiol on release and disposition of norepinephrine from nerve endings. Am J Physiol 1980; 239: H450–6

    PubMed  CAS  Google Scholar 

  73. Jiang C, Sarrel PM, Lindsay DC, et al. Endothelium-independent relaxation of rabbit coronary artery by 17fl-oestradiol in vitro. Br J Pharmacol 1991; 104: 1033–7

    PubMed  CAS  Google Scholar 

  74. Chester AH, Jiang C, Borland JA, et al. Estrogen relaxes human epicardial coronary arteries through non-endothelium-dependent mechanisms. Coron Artery Dis 1995; 6: 417–22

    PubMed  CAS  Google Scholar 

  75. Martin W, Villani GM, Jothianandan D, et al. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther 1985; 232: 708–16

    PubMed  CAS  Google Scholar 

  76. Stice SL, Ford SP, Rosazza JP, et al. Role of 4-hydroxylated estradiol in reducing Ca2+ uptake of uterine arterial smooth muscle cells through potential-sensitive channels. Biol Reprod 1987; 36: 361–8

    PubMed  CAS  Google Scholar 

  77. Stice SL, Ford SP, Rosazza JP, et al. Interaction of 4-hydroxylated estradiol and potential-sensitive Ca2+ channels in altering uterine blood flow during the estrous cycle and early pregnancy in gilts. Biol Reprod 1987; 36: 369–75

    PubMed  CAS  Google Scholar 

  78. Jiang C, Poole-Wilson PA, Sarrel PM, et al. Effect of 17β-oestradiol on contraction, Cal+ current and intracellular free Ca2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol 1992; 106: 739–45

    PubMed  CAS  Google Scholar 

  79. Henry PD, Bentley KI. Suppression of atherogenesis in cholesterol fed rabbits treated with nifedipine. J Clin Invest 1981; 68: 1366–9

    PubMed  CAS  Google Scholar 

  80. Lichtlen PR, Hugenholtz PG, Hecker H. et al. Retardation of angiographie progression of coronary artery disease by nifedipine. Lancet 1990; 335: 1109–13

    PubMed  CAS  Google Scholar 

  81. Rosano GMC, Lopez Hidalgo M, Arie S, et al. Acute effect of estradiol 17β upon coronary reactivity in menopausal women with coronary artery disease [abstract]. Eur Heart J 1996; 17

    Google Scholar 

  82. Jiang C, Sarrel PM, Poole-Wilson PA, et al. Acute effect of 17fi-estradiol on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol 1992; 26: H271–5

    Google Scholar 

  83. Lerman A, Webster MWI, Chesebro JH, et al. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation 1993; 88: 2923–8

    PubMed  CAS  Google Scholar 

  84. Rosano GMC, Pereira WI, Arie S, et al. Acute administration of estradiol 17β reduces andithelin-1 release from the ischemic myocardium of menopausal women with coronary artery disease. J Am Coll Cardiol 1997; 2Suppl. A: 210A

    Google Scholar 

  85. Nachtigall LE, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54: 74–9

    PubMed  CAS  Google Scholar 

  86. Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after estrogen and estrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821–8

    PubMed  CAS  Google Scholar 

  87. Psaty BM, Heckberr SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154: 1333–9

    PubMed  CAS  Google Scholar 

  88. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37

    PubMed  CAS  Google Scholar 

  89. Pederson TR, Kjekahus J, Berg K. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastin Survival Study (4S). Lancet 1994; 344: 1383–9

    Google Scholar 

  90. Tikkanen MJ. Postmenopausal hormone replacement therapy: effects of progestogens on serum lipids and lipoproteins: a review. Maturitas 1986; 8: 7–17

    PubMed  CAS  Google Scholar 

  91. Krauss RM. Effects of progestational agents on serum lipids and lipoproteins. J Reprod Med 1982; 27: 503–10

    PubMed  CAS  Google Scholar 

  92. Rijpkema AHM, Van Den Sanden AA, Ruijs AHC. Effects of postmenopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990; 12: 259–85

    PubMed  CAS  Google Scholar 

  93. Jarrett RJ, Graver HJ. Changes in oral glucose turnover during the menstrual cycle. BMJ 1968; 2: 528–9

    PubMed  CAS  Google Scholar 

  94. Adams MR, Kaplan JR, Manuck SB, et al. Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Ateriosclerosis 1990; 10: 1051–7

    CAS  Google Scholar 

  95. Jiang C, Sarrel PM, Lindsay DC, et al. Progesterone induces endothelium-independent relaxation of rabbit coronary artery in vitro. Eur J Pharmacol 1992; 211: 163–7

    PubMed  CAS  Google Scholar 

  96. Miller VM, Vanhoutte PM. Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am JPhysiol 1991; 261: R1022–7

    CAS  Google Scholar 

  97. Rosano GMC, Leonardo F, Cerquetani E, et al. Comparative effects of continuous combined hormone replacement therapy regimens on brachial artery blood flow [abstract]. J Am Coll Cardiol 1998; 2Suppl. A.: 459A

    Google Scholar 

  98. Rosano GMC, Chierchia SL, Morgagni GL, et al. Effect of the association of different progestogens to estradiol 17β therapy upon effort-induced myocardial ischemia in female patients with coronary artery disease. J Am Coll Cardiol 1997; 2Suppl. A: 344A

    Google Scholar 

  99. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102: 319–24

    PubMed  CAS  Google Scholar 

  100. Price TM, Blauer KL, Hansen M, et al. Single-dose pharmacokinetics of sublingual versus oral administration of micronized estradiol 17β. Obstet Gynecol 1997; 89: 340–5

    PubMed  CAS  Google Scholar 

  101. Casper RF, Yen SSC. Rapid absorption of micronized estradiol 17β following sublingual administration. Obstet Gynecol 1981; 57: 62–4

    PubMed  CAS  Google Scholar 

  102. Woodruff DJ, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (pre-marin) with medroxyprogesterone acetate or conjugated estrogens alone: for the Menopause Study Group. Am J Obstet Gynecol 199; 170: 1213–23

  103. The Writing Group of PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1996; 276: 1389–96

    Google Scholar 

  104. The Writing Group of PEPI Trial. Effects of hormone replacement therapy on endometrial hystology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1996; 275: 370–5

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Istituto H San Raffaele, Milan, Italy

    Giuseppe M. C. Rosano & Gaia Panina

Authors
  1. Giuseppe M. C. Rosano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gaia Panina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe M. C. Rosano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosano, G.M.C., Panina, G. Cardiovascular Pharmacology of Hormone Replacement Therapy. Drugs Aging 15, 219–234 (1999). https://doi.org/10.2165/00002512-199915030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199915030-00005

Keywords

Search

Navigation